Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, has announced the completion of patient dosing in the Phase 2 portion of their Phase 2/3 RePOSA study evaluating IHL-42X, an oral once-daily treatment for obstructive sleep apnea (OSA). The end-of-study follow-up assessments are on track to conclude by May 17, 2025, with topline results expected in July 2025. The company is preparing for an end-of-Phase 2 meeting with the FDA, marking a pivotal period in advancing IHL-42X as a potential first-in-class oral treatment for millions affected by OSA. Phase 3 of the study is set to be conducted exclusively in the United States, with plans to recruit 440 patients.